Cyclin D1 binding to the androgen receptor (AR) NH2-terminal domain inhibits activation function 2 association and reveals dual roles for AR corepression

Molecular Endocrinology

Volumn 19, Issue 3, 2005, Pages 607-620

  Burd, C J ^a   Petre, C E ^a   Moghadam, H ^a   Wilson, E M ^b   Knudsen, Karen E ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; CYCLIN D1; HISTONE DEACETYLASE;

AMINO TERMINAL SEQUENCE; ARTICLE; CANCER GROWTH; CONTROLLED STUDY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN BINDING; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PROTEIN INTERACTION;

ADENOCARCINOMA; AMINO ACID MOTIFS; BINDING SITES; CELL LINE, TUMOR; CYCLIN D1; DOSE-RESPONSE RELATIONSHIP, DRUG; GENES, REPORTER; HUMANS; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MALE; PLASMIDS; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN STRUCTURE, TERTIARY; RECEPTORS, ANDROGEN; TRANSCRIPTION, GENETIC; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 14844333265     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2004-0266     Document Type: Article

References (62)

1. Trapman J, Brinkmann AO 1996 The androgen receptor in prostate cancer. Pathol Res Pract 192:752-760
2. Isaacs JT 1984 Antagonistic effect of androgen on prostatic cell death. Prostate 5:545-557
3. Taplin ME, Balk SP 2004 Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence. J Cell Biochem 91:483-490
4. Gelmann EP 2002 Molecular biology of the androgen receptor. J Clin Oncol 20:3001-3015
5. Leewansangtong S, Soontrapa S 1999 Hormonal ablation therapy for metastatic prostatic carcinoma: a review. J Med Assoc Thai 82:192-205
6. Cooperberg MR, Small EJ, D'Amico A, Carroll PR 2003 The evolving role of androgen deprivation therapy in the management of prostate cancer. Minerva Urol Nefrol 55: 219-238
7. Feldman BJ, Feldman D 2001 The development of androgen-independent prostate cancer. Nat Rev Cancer 1:34-45
8. Pratt WB, Toft DO 1997 Steroid receptor interactions with heat shock protein and immunophilin chaperones. Endocr Rev 18:306-360
9. Chang CS, Kokontis J, Liao ST 1988 Molecular cloning of human and rat complementary DNA encoding androgen receptors. Science 240:324-326
10. Zhou ZX, Sar M, Simental JA, Lane MV, Wilson EM 1994 A ligand-dependent bipartite nuclear targeting signal in the human androgen receptor. Requirement for the DNA-binding domain and modulation by NH2-terminal and carboxyl-terminal sequences. J Biol Chem 269: 13115-13123
11. Jenster G 1998 Coactivators and corepressors as mediators of nuclear receptor function: an update. Mol Cell Endocrinol 143:1-7
12. Langley E, Zhou ZX, Wilson EM 1995 Evidence for an anti-parallel orientation of the ligand-activated human androgen receptor dimer. J Biol Chem 270: 29983-29990
13. Brinkmann AO, Blok LJ, de Ruiter PE, Doesburg P, Steketee K, Berrevoets CA, Trapman J 1999 Mechanisms of androgen receptor activation and function. J Steroid Biochem Mol Biol 69:307-313
14. Jenster G, van der Korput JA, Trapman J, Brinkmann AO 1992 Functional domains of the human androgen receptor. J Steroid Biochem Mol Biol 41:671-675
15. Hong H, Kohli K, Trivedi A, Johnson DL, Stallcup MR 1996 GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. Proc Natl Acad Sci USA 93:4948-4952
16. Berrevoets CA, Doesburg P, Steketee K, Trapman J, Brinkmann AO 1998 Functional interactions of the AF-2 activation domain core region of the human androgen receptor with the amino-terminal domain and with the transcriptional coactivator TIF2 (transcriptional intermediary factor 2). Mol Endocrinol 12:1172-1183
17. Alen P, Claessens F, Verhoeven G, Rombauts W, Peelers B 1999 The androgen receptor amino-terminal domain plays a key role in p160 coactivator-stimulated gene transcription. Mol Cell Biol 19:6085-6097
18. Jenster G, van der Korput HA, van Vroonhoven C, van der Kwast TH, Trapman J, Brinkmann AO 1991 Domains of the human androgen receptor involved in steroid binding, transcriptional activation, and subcellular localization. Mol Endocrinol 5:1396-404
19. Rundlett SE, Wu XP, Miesfeld RL 1990 Functional characterizations of the androgen receptor confirm that the molecular basis of androgen action is transcriptional regulation. Mol Endocrinol 4:708-714
20. Jenster G, van der Korput HA, Trapman J, Brinkmann AO 1995 Identification of two transcription activation units in the N-terminal domain of the human androgen receptor. J Biol Chem 270:7341-7346
21. Simental JA, Sar M, Lane MV, French FS, Wilson EM 1991 Transcriptional activation and nuclear targeting signals of the human androgen receptor. J Biol Chem 266: 510-518
22. Metzger E, Muller JM, Ferrari S, Buettner R, Schule R 2003 A novel inducible transactivation domain in the androgen receptor: implications for PRK in prostate cancer. EMBO J 22:270-280
23. Collingwood TN, Urnov FD, Wolffe AP 1999 Nuclear receptors: coactivators, corepressors and chromatin remodeling in the control of transcription. J Mol Endocrinol 23:255-275
24. Bevan C, Parker M 1999 The role of coactivators in steroid hormone action. Exp Cell Res 253:349-356
25. Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG 1999 The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol 19:8383-8392
26. Chen H, Lin RJ, Schiltz RL, Chakravarti D, Nash A, Nagy L, Privalsky ML, Nakatani Y, Evans RM 1997 Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. Cell 90:569-580
27. Louie MC, Yang HQ, Ma AH, Xu W, Zou JX, Kung HJ, Chen HW 2003 Androgen-induced recruitment of RNA polymerase II to a nuclear receptor-pi 60 coactivator complex. Proc Natl Acad Sci USA 100:2226-2230
28. DiRenzo J, Shang Y, Phelan M, Sif S, Myers M, Kingston R, Brown M 2000 BRG-1 is recruited to estrogen-responsive promoters and cooperates with factors involved in histone acetylation. Mol Cell Biol 20:7541-7549
29. Voegel JJ, Heine MJ, Tini M, Vivat V, Chambon P, Gronemeyer H 1998 The coactivator TIF2 contains three nuclear receptor-binding motifs and mediates transactivation through CBP binding-dependent and -independent pathways. EMBO J 17:507-519
30. Heery DM, Kalkhoven E, Hoare S, Parker MG 1997 A signature motif in transcriptional co-activators mediates binding to nuclear receptors. Nature 387:733-736
31. He B, Kemppainen JA, Voegel JJ, Gronemeyer H, Wilson EM 1999 Activation function 2 in the human androgen receptor ligand binding domain mediates interdomain communication with the NH(2)-terminal domain. J Biol Chem 274:37219-37225
32. Ikonen T, Palvimo JJ, Janne OA 1997 Interaction between the amino- and carboxyl-terminal regions of the rat androgen receptor modulates transcriptional activity and is influenced by nuclear receptor coactivators. J Biol Chem 272:29821-29828
33. He B, Kemppainen JA, Wilson EM 2000 FXXLF and WXXLF sequences mediate the NH2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 275:22986-22994
34. Doesburg P, Kuil CW, Berrevoets CA, Steketee K, Faber PW, Mulder E, Brinkmann AO, Trapman J 1997 Functional in vivo interaction between the amino-terminal, transactivation domain and the ligand binding domain of the androgen receptor. Biochemistry 36:1052-1064
35. Langley E, Kemppainen JA, Wilson EM 1998 Intermolecular NH2-/carboxyl-terminal interactions in androgen receptor dimerization revealed by mutations that cause androgen insensitivity. J Biol Chem 273:92-101
36. Knudsen KE, Cavenee WK, Arden KC 1999 D-type cyclins complex with the androgen receptor and inhibit its transcriptional transactivation ability. Cancer Res 59: 2297-2301
37. Reutens AT, Fu M, Wang C, Albanese C, McPhaul MJ, Sun Z, Balk SP, Janne OA, Palvimo JJ, Pestell RG 2001 Cyclin D1 binds the androgen receptor and regulates hormone-dependent signaling in a p300/CBP-associated factor (P/CAF)-dependent manner. Mol Endocrinol 15:797-811
38. Ewen ME, Lamb J 2004 The activities of cyclin D1 that drive tumorigenesis. Trends Mol Med 10:158-162
39. Coqueret O 2002 Linking cyclins to transcriptional control. Gene 299:35-55
40. Zwijsen RM, Buckle RS, Hijmans EM, Loomans CJ, Bernards R 1998 Ligand-independent recruitment of steroid receptor coactivators to estrogen receptor by cyclin D1. Genes Dev 12:3488-3498
41. Lin HM, Zhao L, Cheng SY 2002 Cyclin D1 Is a ligand-independent co-repressor for thyroid hormone receptors. J Biol Chem 277:28733-28741
42. Petre CE, Wetherill YB, Danielsen M, Knudsen KE 2002 Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem 277: 2207-2215
43. Bienvenu F, Gascan H, Coqueret O 2001 Cyclin D1 represses STAT3 activation through a Cdk4-independent mechanism. J Biol Chem 276:16840-16847
44. Petre-Draviam CE, Cook SL, Burd CJ, Marshall TW, Wetherill YB, Knudsen KE 2003 Specificity of cyclin D1 for androgen receptor regulation. Cancer Res 63: 4903-4913
45. Martinez ED, Danielsen M 2002 Loss of androgen receptor transcriptional activity at the G(1)/S transition. J Biol Chem 277:29719-29729
46. Linja MJ, Porkka KP, Kang Z, Savinainen KJ, Janne OA, Tammela TL, Vessella RL, Palvimo JJ, Visakorpi T 2004 Expression of androgen receptor coregulators in prostate cancer. Clin Cancer Res 10:1032-1040
47. Lim J, Ghadessy FJ, Abdullah AA, Pinsky L, Trifiro M, Yong EL 2000 Human androgen receptor mutation disrupts ternary interactions between ligand, receptor domains, and the coactivator TIF2 (transcription intermediary factor 2). Mol Endocrinol 14:1187-1197
48. He B, Lee LW, Minges JT, Wilson EM 2002 Dependence of selective gene activation on the androgen receptor NH2- and COOH-terminal interaction. J Biol Chem 277: 25631-25639
49. Shenk JL, Fisher CJ, Chen SY, Zhou XF, Tillman K, Shemshedini L 2001 p53 Represses androgen-induced transactivation of prostate-specific antigen by disrupting hAR amino- to carboxyl-terminal interaction. J Biol Chem 276:38472-38479
50. Wang Q, Lu J, Yong EL 2001 Ligand- and coactivator-mediated transactivation function (AF2) of the androgen receptor ligand-binding domain is inhibited by the cognate hinge region. J Biol Chem 276:7493-7499
51. Minamiguchi K, Kawada M, Ohba S, Takamoto K, Ishizuka M 2004 Ectopic expression of the amino-terminal peptide of androgen receptor leads to androgen receptor dysfunction and inhibition of androgen receptor-mediated prostate cancer growth. Mol Cell Endocrinol 214: 175-187
52. Wang C, Pattabiraman N, Zhou JN, Fu M, Sakamaki T, Albanese C, Li Z, Wu K, Hulit J, Neumeister P, Novikoff PM, Brownlee M, Scherer PE, Jones JG, Whitney KD, Donehower LA, Harris EL, Rohan T, Johns DC, Pestell RG 2003 Cyclin D1 repression of peroxisome proliferator-activated receptor γ expression and transactivation. Mol Cell Biol 23:6159-6173
53. Steketee K, Berrevoets CA, Dubbink HJ, Doesburg P, Hersmus R, Brinkmann AD, Trapman J 2002 Amino acids 3-13 and amino acids in and flanking the 23FxxLF27 motif modulate the interaction between the N-terminal and ligand-binding domain of the androgen receptor. Eur J Biochem 269:5780-5791
54. He B, Wilson EM 2003 Electrostatic modulation in steroid receptor recruitment of LXXLL and FXXLF motifs. Mol Cell Biol 23:2135-2150
55. McMahon C, Suthiphongchai T, DiRenzo J, Ewen ME 1999 P/CAF associates with cyclin D1 and potentiates its activation of the estrogen receptor. Proc Natl Acad Sci USA 96:5382-5387
56. Petre-Draviam CE, Williams EB, Burd CJ, Gladden A, Moghadam H, Meller J, Diehl JA, Knudsen KE 2005 A central domain of cyclin D1 mediates nuclear receptor co-repressor activity. Oncogene 24:431-444
57. Thompson J, Saatcioglu F, Janne OA, Palvimo JJ 2001 Disrupted amino- and carboxyl-terminal interactions of the androgen receptor are linked to androgen insensitivity. Mol Endocrinol 15:923-935
58. He B, Bowen NT, Minges JT, Wilson EM 2001 Androgen-induced NH2- and COOH-terminal interaction inhibits p160 coactivator recruitment by activation function 2. J Biol Chem 276:42293-42301
59. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, Wilson EM 2001 A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res 61: 4315-4319
60. Liao G, Chen LY, Zhang A, Godavarthy A, Xia F, Ghosh JC, Li H, Chen JD 2003 Regulation of androgen receptor activity by the nuclear receptor corepressor SMRT. J Biol Chem 278:5052-5061
61. Agoulnik IU, Krause WC, Bingman III WE, Rahman HT, Amrikachi M, Ayala GE, Weigel NL 2003 Repressors of androgen and progesterone receptor action. J Biol Chem 278:31136-31148
62. Altincicek B, Tenbaum SP, Dressel U, Thormeyer D, Renkawitz R, Baniahmad A 2000 Interaction of the corepressor Alien with DAX-1 is abrogated by mutations of DAX-1 involved in adrenal hypoplasia congenita. J Biol Chem 275:7662-7667